Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Nodthera Ltd.
Headquarters: Cambridge, United Kingdom
Website: https://nodthera.com
Year Founded: 2016
Status: Private
BioCentury | Aug 6, 2024
Management Tracks
A trio of hires at 4D
Plus: Madrigal hires Shannon Kelley as general counsel, and updates from NodThera, Dragonfly, AusBiotech and more
BioCentury | Jun 19, 2024
Product Development
Clinical Report: Zentalis hold resurfaces WEE1 safety concerns
Plus data from BioNTech, MediLink, Nurix, Aerovate and more
BioCentury | May 29, 2024
Management Tracks
Nurix promotes O’Connor to CMO, Phiasivongsa to CTO
Plus: NodThera names Daniel Swisher CEO, and updates from Cogent, Sapreme and Biocom
BioCentury | May 23, 2024
Emerging Company Profile
Halia: Leveraging RAB10 as a new lens on the NLRP3 inflammasome
Guided by human variation in the GTPase RAB10, Utah-based company seeks to disrupt inflammasome assembly
BioCentury | Apr 24, 2024
Product Development
Clinical report: Sanofi data advances pair of autoimmune disease mechanisms
Plus: Neurocrine hits in Phase II depression study and updates from Cerevel, Sage, Ventus, Lilly and AbbVie
BioCentury | Mar 18, 2024
Product Development
Treating obesity by quelling inflammation in the brain
How NLRP3 inhibitors could extend durability and enhance CV benefits over GLP-1 therapies alone
BioCentury | Apr 4, 2023
Management Tracks
Eyeing deals, Biogen names Keeney head of corporate development
Plus: Flamingo hires a new CMO, and updates from Arkuda and GeneDx
BioCentury | Dec 16, 2022
Data Byte
NLRP3 clinical progress
New data from EpicentRx boost confidence in NLRP3 as a cancer target, with a pair of autoimmune programs not far behind
BioCentury | Sep 29, 2022
Deals
In NLRP3 deal with Novo, Ventus fences off some indications for itself
‘Pragmatic’ deal gives Novo set of cardiometabolic, kidney and liver diseases, while Versant-backed Ventus keeps indications within biotech’s scope
BioCentury | Jun 23, 2022
Management Tracks
Expanded role for Pfizer’s Allerton
Plus Melvin becomes COO at Viridian and updates from Oragenics and Transine
Items per page:
1 - 10 of 32